After Aimmune (AIMT) announced a renewal of its relationship with Nestle (NSRGY) at terms very similar to the prior deal, Piper Jaffray analyst Christopher Raymond said he views this deal as "one of the more attractive in all of biopharma," given that a large commercial partner has provided funding with no commercial rights in return. Importantly, Aimmune retains worldwide development and commercialization rights to AR101, noted Raymond, who continues to recommending the stock ahead of what he sees as the eventual approval and launch of AR101. Raymond keeps an Overweight rating on Aimmune with a $60 price target.